Portal de Periódicos da CAPES

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

2013; Elsevier BV; Volume: 38; Issue: 1 Linguagem: Inglês

10.1016/j.leukres.2013.07.023

1873-5835

Thomas Prébet, Thorsten Braun, Odile Beyne‐Rauzy, François Dreyfus, Aspasia Stammatoullas, Eric Wattel, Shanti Amé, Emmanuel Raffoux, Jacques Delaunay, Aude Charbonnier, Lionel Adès, Pierre Fenaux, Norbert Vey,

Pneumocystis jirovecii pneumonia detection and treatment

Outcome of patients with myelodysplastic syndrome after azacitidine failure is poor. In this population, we combined cytarabine (10–20 mg/m2/day 14 days) with vorinostat (400 mg/day) for escalating durations (7 days, 10 days and 14 days), and starting on day 1 (concomitant arm) or on day 14 (sequential arm) following a 3 + 3 phase I design. 40 patients were treated. Dose limiting toxicities were all seen in sequential arm. The overall response rate was 15% with 4 responses in concomitant arm (ORR = 25%). We conclude that this combination is tolerable and concomitant administration might be less toxic and have better therapeutic effect (clinicaltrials.gov NCT00776503).